MD, PhD, MBA
Dr. David Greene, MD, PhD, MBA, stands at the forefront of regenerative medicine and healthcare innovation, blending clinical expertise with entrepreneurial vision. As the founder and CEO of R3 Stem Cell and US Lead Network, Dr. Greene has dedicated his career to advancing patient care and empowering medical practices through advanced therapies and digital marketing excellence.
A residency and fellowship-trained orthopedic surgeon, Dr. Greene began his journey in medicine with a deep commitment to helping others. After years in clinical practice, he recognized the transformative potential of regenerative therapies and the urgent need for better patient access and education. This insight led him to establish R3 Stem Cell, now a global leader in non-surgical treatment options using stem cell and PRP therapy. Under his leadership, R3 Stem Cell has performed over 26,000 procedures across more than 45 international clinics, offering hope and healing to patients worldwide.
Dr. Greene’s entrepreneurial spirit didn’t stop at clinical innovation. He also founded US Lead Network, a healthcare internet marketing company that leverages artificial intelligence to help medical and dental practices grow their patient base efficiently and ethically. His two books on healthcare internet marketing have become essential reading for providers seeking to navigate the complexities of digital patient acquisition. Recognized as a Top 20 Expert Author by Ezines.com – ranking #15 out of over 470,000 authors and #1 in Pain Management – Dr. Greene’s thought leadership has shaped the way healthcare professionals connect with patients online.
A defining moment in Dr. Greene’s career was his decision to leave clinical practice and focus entirely on innovation and education. “I’ve never been a fan of just settling for the status quo. Innovation is a cornerstone of what makes America great,” he reflects. This philosophy has driven R3 Stem Cell’s mission to provide affordable, high-quality regenerative care and to demystify stem cell therapies through comprehensive training courses and educational content for both providers and patients.
Dr. Greene’s work has garnered international recognition, including a feature on the cover of Corporate Vision magazine, where his commitment to affordable, accessible regenerative therapies was spotlighted. His impact extends beyond business metrics – he is known for his compassionate approach, always prioritizing patient education and ethical practice.
Outside of his professional life, Dr. Greene is inspired by the words of Maya Angelou: “My mission in life is not merely to survive, but to thrive; and to do so with some passion, some compassion, some humor, and some style”. He brings this ethos to his daily work, fostering a culture of innovation, empathy, and continuous learning.
When he’s not leading global healthcare initiatives, Dr. Greene enjoys sharing insights on social media, connecting with colleagues, and pursuing personal interests that keep him grounded and inspired.
Dr. David Greene’s journey is a testament to the power of combining clinical skill, business acumen, and a heartfelt commitment to making a difference – one patient, one practice, and one innovation at a time.
All Posts
Hidradenitis Suppurativa (often abbreviated as HS) is a chronic, recurrent inflammatory skin condition that originates in the terminal hair follicles. It most commonly affects skin-on-skin areas where apocrine sweat glands are concentrated, including the armpits (axilla), beneath the breasts (inframammary folds), and the groin. For
Undergoing major surgery—whether a total joint replacement, rotator cuff repair, or tendon reconstruction—requires significant physical commitment and extensive rehabilitation. While surgical techniques continue to advance, post-operative recovery often involves prolonged inflammation, pain management challenges, and lengthy time away from daily activities or sports. To optimize
Understanding Ankylosing Spondylitis and the Search for Better Treatments Ankylosing Spondylitis (AS) is a chronic inflammatory autoimmune disease primarily affecting the axial skeleton, particularly the sacroiliac joints and the spine. Over time, persistent inflammation can lead to severe back pain, structural stiffness, and, in advanced
Fibromyalgia is one of the most challenging chronic pain conditions to diagnose and treat. For many, arriving at a diagnosis feels less like receiving a definitive answer and more like being given a label of exclusion—a term applied when extensive testing fails to identify another
In the rapidly evolving field of regenerative medicine, patients researching advanced options for tissue repair, chronic inflammation, or degenerative conditions frequently encounter two prominent terms: stem cells and exosomes. While both play central roles in cellular repair and healing mechanisms, they are fundamentally distinct in
As interest in regenerative medicine continues to expand globally, Asia—and specifically the Philippines—has emerged as a major hub for international patients seeking advanced cell therapies. Individuals traveling from countries such as Australia, Malaysia, Thailand, and Japan often look to the region for accessible, high-quality care.
Navigating the landscape of regenerative medicine can feel overwhelming. With emerging cell therapies regularly reaching clinical practice, patients and families searching for advanced treatment options often encounter complex scientific terms like multipotent, pluripotent, and MUSE cells. Understanding the differences between these cell types is essential
For women diagnosed with Premature Ovarian Failure (POF)—also clinically known as Primary Ovarian Insufficiency (POI)—the physical and emotional toll of reproductive decline before age 40 can be overwhelming. Defined by the premature loss of normal ovarian function, POF leads to a sharp decline in estrogen
Duchenne Muscular Dystrophy (DMD) is a progressive X-linked genetic disorder primarily affecting males, occurring in approximately 1 in 3,500 to 5,000 live male births worldwide. DMD is characterized by the absence or severe deficiency of dystrophin, an essential structural protein that acts as an anchor
Chronic respiratory conditions—such as Chronic Obstructive Pulmonary Disease (COPD), pulmonary fibrosis, post-viral residual lung dysfunction, and severe hyper-reactive airway disorders—present persistent challenges for patients seeking long-term relief. Traditional management focuses primarily on symptom control, bronchodilators, supplemental oxygen, and corticosteroids to slow disease progression. In recent
